Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

Her2 was far off from anything,and was going to be a major cash burn. If the data was`nt staggering enough to bring in a partner for it before they were to start the next phase trial,then Adxs made the right decision,or would you rather them spend shareholder money on it by continuing to go it alone? Not me,I say shelf temporarily until we get our approval for Axal,and if in the meantime a suitor comes along to take it,then wonderful,but Adxs lost nothing,they just made another smart move by prioritizing their balance sheet to increase shareholder value. Going it alone on HER 2,on top of everything else the companies is paying for itself,is too much for the current balance sheet,and it would`ve have caused dilution, to continue it alone. Shareholders got saved with this move,they just don`t see it clearly yet...